Genitourinary Cancers | Tumor

Prostate Cancer Questions Answered on Surgery, Side Effects and More

September 27th 2024, 7:00pm

Article

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function.

Supplemental New Drug Application Submitted for Nubeqa in Prostate Cancer Subset

September 27th 2024, 1:00pm

Article

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Kidney Cancer Questions Answered, From Protein Intake to Clinical Trials

September 26th 2024, 3:00pm

Article

An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

Kidney Cancer FAQs Answered on Treatments, Care Teams and More

September 24th 2024, 7:00pm

Article

An expert provides answers to pressing questions regarding different aspects of a kidney cancer journey, including stage, grade and treatment options.

Nubeqa Plus ADT Outperformed ADT Alone in Treating Prostate Cancer

September 23rd 2024, 9:00pm

Article

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

Challenges to Consider While Receiving Fotivda for Kidney Cancer

September 21st 2024, 2:00pm

Video

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma

September 20th 2024, 7:00pm

Article

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

Swimsuit Model Reveals Ovarian Cancer, Hockey Pro Shares Diagnosis and More

September 20th 2024, 3:00pm

Article

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in the oncology space this week.

Survival Rate Increased With Yervoy-Opdivo Combo in Kidney Cancer

September 20th 2024, 1:00pm

Article

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo.

Trodelvy May Improve Responses in Bladder Cancer Subtype

September 18th 2024, 3:00pm

Article

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed after checkpoint inhibitors.